The web revenue got here on a greater than 11% enhance in whole income from operations to ₹.8,572.1 crore (₹.7,696.1 crore), the outcomes ready as per Indian Accounting Standards (Ind AS) confirmed.
Pricing strain on most cancers drug Lenalidomide is predicted to accentuate within the U.S. generics market, in accordance with co-chairman and MD G.V. Prasad. He stated this reaffirming the corporate’s concentrate on strengthening the bottom enterprise by supply of our pipeline property, enhancing total productiveness and enterprise growth.”
On section income, the corporate stated world generics contributed ₹7,573.2 crore (₹.6,892.9 crore), whereas share of Pharmaceutical Services and Active Ingredients declined to ₹987.4 crore (₹1,047.2 crore).
In a launch, on the outcomes ready as per International Financial Reporting Standards (IFRS), Dr. Reddy’s stated income from the North America generics market at ₹3,410 crore was 11% decrease a decline YoY of and 4% QoQ. The decline was primarily as a consequence of elevated worth erosion in sure key merchandise, together with Lenalidomide. Revenue from generics gross sales in Europe, India and Emerging Markets have been larger yr on yr.
The firm’s shares closed lower than 1% larger at ₹1,247.55 every on the BSE.
Published – July 23, 2025 07:12 pm IST
No Comment! Be the first one.